 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || exebacase (CF-301) / ContraFect, tonabacase (LSVT-1701) / Roivant, Basilea
Review, Journal: Bacteriophages as a potential substitute for antibiotics: A comprehensive review. (Pubmed Central) - Apr 24, 2024
Many commercially available endolysins such as Staphefekt SA.100, Exebacase (CF-301), and N-Rephasin
- | tonabacase (LSVT-1701) / Roivant
Enrollment change, Trial withdrawal: ERASE: ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis (clinicaltrials.gov) - Jun 30, 2022
P2, N=0, Withdrawn, Sponsor: Lysovant
Many commercially available endolysins such as Staphefekt SA.100, Exebacase (CF-301), and N-Rephasin N=12 --> 0 | Recruiting --> Withdrawn
- || tonabacase (LSVT-1701) / Roivant
Enrollment open: ERASE: ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis (clinicaltrials.gov) - May 12, 2022
P2, N=12, Recruiting, Sponsor: Lysovant
N=12 --> 0 | Recruiting --> Withdrawn Not yet recruiting --> Recruiting
- | tonabacase (LSVT-1701) / Roivant
New P2 trial: ERASE: ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis (clinicaltrials.gov) - Apr 13, 2022
P2, N=12, Not yet recruiting, Sponsor: Lysovant
- || tonabacase (LSVT-1701) / Roivant
Clinical, P1 data, PK/PD data, Journal: A Phase 1 Study to Evaluate the Safety and Pharmacokinetics following Administration of Single and Multiple Doses of the Anti-Staphylococcal Lysin, LSVT-1701, in Healthy Adult Subjects. (Pubmed Central) - Mar 24, 2022
P1b
Treatment-emergent adverse events (TEAEs) were predominantly of mild intensity. The most common TEAEs were chills, pyrexia, headache, infusion site events, cough, rhinorrhea, and increases in C-reactive protein.
- ||| tonabacase (LSVT-1701) / Roivant
Trial termination: Phase IIa Clinical Study of N-Rephasin (clinicaltrials.gov) - Aug 18, 2021
P2a, N=25, Terminated, Sponsor: Intron Biotechnology, Inc.
The most common TEAEs were chills, pyrexia, headache, infusion site events, cough, rhinorrhea, and increases in C-reactive protein. Completed --> Terminated; Enrollment into this study was terminated by the Sponsor prior to completion for strategic reasons.
- |||| tonabacase (LSVT-1701) / Roivant
Trial completion, Enrollment change: Phase IIa Clinical Study of N-Rephasin (clinicaltrials.gov) - Jan 29, 2021
P2a, N=25, Completed, Sponsor: Intron Biotechnology, Inc.
Completed --> Terminated; Enrollment into this study was terminated by the Sponsor prior to completion for strategic reasons. N=50 --> 25 | Recruiting --> Completed
- || tonabacase (LSVT-1701) / Roivant, Basilea
Trial completion: A Study to Evaluate the Safety, PK, PD, Immunogenicity of N-Rephasin (clinicaltrials.gov) - Jan 29, 2021
P1b, N=33, Completed, Sponsor: Intron Biotechnology, Inc.
N=50 --> 25 | Recruiting --> Completed Recruiting --> Completed
- | tonabacase (LSVT-1701) / Roivant
Trial completion date, Trial primary completion date: Phase IIa Clinical Study of N-Rephasin (clinicaltrials.gov) - Aug 8, 2018
P2a, N=50, Recruiting, Sponsor: Intron Biotechnology, Inc.
Recruiting --> Completed Trial completion date: Jul 2018 --> Apr 2020 | Trial primary completion date: May 2018 --> Jan 2020
- | tonabacase (LSVT-1701) / Roivant, Basilea
New P1 trial: A Study to Evaluate the Safety, PK, PD, Immunogenicity of N-Rephasin (clinicaltrials.gov) - Feb 25, 2018
P1b, N=40, Recruiting, Sponsor: Intron Biotechnology, Inc.
- | tonabacase (LSVT-1701) / Roivant
Enrollment open: Phase IIa Clinical Study of N-Rephasin (clinicaltrials.gov) - Apr 22, 2017
P2a, N=50, Recruiting, Sponsor: Intron Biotechnology, Inc.
Trial completion date: Jul 2018 --> Apr 2020 | Trial primary completion date: May 2018 --> Jan 2020 Not yet recruiting --> Recruiting
- | tonabacase (LSVT-1701) / Roivant
New P2a trial: Phase IIa Clinical Study of N-Rephasin (clinicaltrials.gov) - Mar 24, 2017
P2a, N=50, Not yet recruiting, Sponsor: Intron Biotechnology, Inc.
- | tonabacase (LSVT-1701) / Roivant, Basilea
Trial completion: A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin (clinicaltrials.gov) - Aug 19, 2014
P1, N=36, Completed, Sponsor: Intron Biotechnology, Inc.
Not yet recruiting --> Recruiting Recruiting --> Completed
- tonabacase (LSVT-1701) / Roivant, Basilea
Trial initiation date: A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin (clinicaltrials.gov) - Aug 14, 2013
P1, N=36, Recruiting, Sponsor: Intron Biotechnology, Inc.
Recruiting --> Completed Initiation date: May 2013 --> Aug 2013
- tonabacase (LSVT-1701) / Roivant, Basilea
Enrollment open: A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin (clinicaltrials.gov) - Aug 14, 2013
P1, N=36, Recruiting, Sponsor: Intron Biotechnology, Inc.
Initiation date: May 2013 --> Aug 2013 Not yet recruiting --> Recruiting
- | tonabacase (LSVT-1701) / Roivant, Basilea
New P1 trial: A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin (clinicaltrials.gov) - May 14, 2013
P1, N=36, Recruiting, Sponsor: Intron Biotechnology, Inc.